ID: ALA361246

Max Phase: Preclinical

Molecular Formula: C28H25N5O

Molecular Weight: 447.54

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCOc1cccc(-c2cc(C#N)ccc2CNCc2cncn2Cc2ccc(C#N)cc2)c1

Standard InChI:  InChI=1S/C28H25N5O/c1-2-34-27-5-3-4-24(13-27)28-12-23(15-30)10-11-25(28)16-31-17-26-18-32-20-33(26)19-22-8-6-21(14-29)7-9-22/h3-13,18,20,31H,2,16-17,19H2,1H3

Standard InChI Key:  ZSITWYGPKGRMKP-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 447.54

Molecular Weight (Monoisotopic): 447.2059

AlogP: 5.03

#Rotatable Bonds: 9

Polar Surface Area: 86.66

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 8.02

CX LogP: 4.56

CX LogD: 3.85

Aromatic Rings: 4

Heavy Atoms: 34

QED Weighted: 0.39

Np Likeness Score: -1.24

References

1. Lin NH, Wang L, Wang X, Wang GT, Cohen J, Gu WZ, Zhang H, Rosenberg SH, Sham HL..  (2004)  Synthesis and biological evaluation of 1-benzyl-5-(3-biphenyl-2-yl-propyl)-1H-imidazole as novel farnesyltransferase inhibitor.,  14  (20): [PMID:15380198] [10.1016/j.bmcl.2004.07.083]

2. Equbal T, Silakari O, Rambabu G, Ravikumar M..  (2007)  Pharmacophore mapping of diverse classes of farnesyltransferase inhibitors.,  17  (6): [PMID:17236767] [10.1016/j.bmcl.2006.12.087]

Source

Source(1):

• Scientific Literature